Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

MEMPHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDAQ: GTXI) announced today that data from the recent Phase II proof of concept clinical trial of Ostarine(TM) and from the ongoing Phase III clinical trial evaluating ACAPODENE(R) (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) will be presented at the upcoming 2007 Annual Meeting of the American Society of Clinical Oncology being held June 1 - 5 at McCormick Place in Chicago.

William J. Evans, PhD, Professor of Geriatrics, Physiology, and Nutrition at the Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences, will present the results of a Phase II proof of concept clinical trial evaluating the effects of Ostarine treatment on lean body mass and functional performance in 120 elderly males and postmenopausal females.

-- "Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients." Poster number: MM2. Abstract number: 9119.

-- Date and time: June 2, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

Matthew R. Smith, MD, PhD, Associate Professor of Medicine at Harvard Medical School and the Lead Principal Investigator of the Phase III ADT clinical trial, will present results of an interim lipid analysis conducted in the first 197 men to complete one year of the trial.

-- "Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy." Poster number: G6. Abstract number: 5124.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

S. Bruce Malkowicz, MD, Professor of Surgery at University of Pennsylvania School of Medicine, will present data detailing the prevalence at baseline of bone loss in patients participating in the Phase III ADT clinical trial.

-- "Prevalence of osteoporosis and osteopenia during androgen deprivation therapy (ADT) for prostate cancer: Baseline data from a large randomized controlled trial." Poster number: F5. Abstract number: 5116.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

About GTx

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertaint ies. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not be able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's quarterly report on form 10-Q filed with the U.S. Securities and Exchange Commission on May 7, 2007, contains under the heading "Risk Factors," a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


GTx, Inc., Memphis
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... "I struggled for years with pain every day. I ... would love to do, I missed. We moved back home from living out of ... first. They have changed my life drastically. I love all of the people involved ...
(Date:11/29/2015)... ... , ... NewsWatch featured X-wing as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... future because flying cars are about to become a reality. Where’s the idea from? ...
(Date:11/29/2015)... ... ... While conventional walkers afford considerable help with mobility, their design does not allow ... from Uniontown, Pa., has found a way to address those needs. , He developed ... to improve the user’s quality of life. To begin with, this improved mobility aid ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic ... distortion effect tool designed specially for Final Cut Pro X. FCPX ... with the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated ... announce their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community ... the tight Bay Area rental market to efficiently find housing suitable to their needs ...
Breaking Medicine News(10 mins):